Link here: After a competitive process, Kurrajong is excited to select Humanetix’s ACE Platform as their new clinical care management platform. This decision will help Kurrajong Nursing Home transition from using paper-based records to transforming into a modern new clinical care platform. ACE will allow Kurrajong Nursing Home to provide better outcomes for their residents […]
Listen to the On the Couch biotech special podcast. Host Henry Jennings sits down with fund manager BioScience Managers and biotechs Biotron and Pharmaxis to discuss what makes a successful biotech and how to invest successfully in the cutting edge of medical science and drug treatments. In this ‘On the Couch’ special, Henry Jennings sits down with two […]
Link: Last month passed away exoskeleton technology pioneer Joseph Zawaideh. He was the Co-Founder and the Vice President of Marketing & Business Development of Levitate Technologies. While Joseph was not a close personal friend with anyone at the Exoskeleton Report, we shared an unshakable belief that occupational exoskeletons can make the life of workers all […]
The Australian, Tuesday, November 8, 2022, Link Here: One of Australia’s best known, and most successful medical breakthroughs has been the burns treatment process developed in Western Australia, which was highlighted after the 2002 Bali bombings. But it is also one of the most tragic. The US has now embraced the Australian technology as its […]
Melbourne, Australia and London, UK – October 13, 2022 ….. BioScience Managers, the international healthcare investment firm, is pleased to announce the appointment of David Atkins MBA PhD in the role of Managing Partner. Working alongside founder and Managing Partner, Jeremy Curnock Cook, David will be responsible for driving the future growth of BioScience Managers […]
MARINA DEL REY, Calif., Aug. 11, 2022 /PRNewswire/ Link here — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update. Second Quarter 2022 and Recent Developments: AP-PA02 advancing […]
Link to full article Key Highlights: • US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company • Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of negotiations with […]
Link to full article April 14, 2022 – Results further support therapeutic potential of Auxora in respiratory diseases and other inflammatory diseases – LA JOLLA, Calif., April 14, 2022 – CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of results from the Company’s CARDEA clinical trial, a Phase […]
Link to full article MARINA DEL REY, Calif., May 23, 2022 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the first patient has been dosed in the company’s Phase 1b/2a clinical trial (‘diSArm’) of AP-SA02, which is […]
Link to full article Melbourne, Australia – 28 April 2022: Adherium (ASX: ADR), a leader in respiratory eHealth, remote monitoring, and data management solutions, announces the release of the latest Hailie® platform integration tools comprised of an advanced Rest application programming interface (API) and a new, updated software development kit (SDK) to improve connection with […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: